

Appendix D

2004 Cardiovascular Biomarkers and Surrogate Endpoints Faculty

Douglas Throckmorton	Director, Cardio-Renal, FDA
David Orloff	Director, Metabolism and Endocrine, FDA
Eric Abadie	European Medicines Agency (EMA)
Ray Lipicky	Former Director, Cardio-Renal, FDA
Robert Temple	Director, Office of Medical Policy, FDA
Claude Lenfant	Director, NIH, NHLBI
Peter Libby	Chief Cardiology, Harvard Medical School/BWH
Robert Harrington	Duke University
Paul Ridker	Professor, Harvard Medical School/Brigham and Womens'
Daniel Rader	University of Pennsylvania
Jay Heinecke	University of Washington
Greg Brown	University of Washington
Stan Hazen	Cleveland Clinic Foundation
Michael Phillips	University of Montreal
Bram Zuckerman	FDA, Director, Division of CV Devices
George Steiner	University of Toronto
George Mensah	Chief, CV Health Program, CDC
Jean-Claude Tardif	Director of Research, Montreal Heart Institute
John Kastelein	Chair, Genetics in CV Disease, University of Amsterdam
Steve Nissen	Director, Cleveland Clinic Foundation
Paolo Raggi	Director, Preventive Cardiology, Tulane
Todd Anderson	Director, Foothills Hospital
Thomas Hatsukami	Vascular Surgery, Washington University
Therese Heinonen	Assoc. Director Medical Affairs, Montreal Heart Institute